The ISPAD Special Interest Group (SIG) on Artificial Intelligence (AI) in Diabetes Care aims to advance understanding, education, implementation, and responsible use of AI technologies across pediatric diabetes care. As AI applications rapidly expand within healthcare, they have the potential to support clinical decision-making, improve diabetes technologies, enhance education, facilitate earlier diagnosis, and optimize healthcare delivery. At the same time, important challenges related to ethics, governance, equity, safety, and implementation must be carefully addressed. Based on the priorities identified by the group and the development of the forthcoming ISPAD Clinical Practice Consensus Guidelines chapter on AI, the SIG will promote a balanced, evidence-informed, and clinically relevant approach to AI in diabetes care.

This SIG will bring together clinicians, researchers, healthcare professionals, educators, technology experts, people living with diabetes, and other stakeholders who share an interest in the responsible integration of AI into pediatric diabetes care. The group will provide an international forum to exchange knowledge, identify opportunities and challenges, develop educational initiatives, and support the generation and dissemination of best practices.

The SIG will focus on key areas including:

  • Defining and promoting a common understanding of AI and its applications in diabetes care.
  • Supporting the development and evaluation of AI-enabled clinical decision-support tools.
  • Exploring the role of AI in improving diabetes technologies and related algorithms.
  • Advancing the use of AI for prediction, risk stratification, and early detection of type 1 diabetes.
  • Promoting responsible implementation of AI in clinical practice.
  • Addressing ethical, legal, privacy, data ownership, and governance considerations.
  • Identifying and mitigating bias in AI systems and datasets.
  • Promoting equitable access to AI innovations across different healthcare settings and regions.
  • Evaluating risks associated with AI technologies, including generative AI systems and inaccurate or misleading outputs.
  • Supporting education initiatives for healthcare professionals, trainees, students, and people living with diabetes.
  • Facilitating collaboration between ISPAD groups, committees, and external partners working in digital health and diabetes technology.
  • Contributing to the development of practical guidance and consensus recommendations for the diabetes community.

The SIG will foster international collaboration and multidisciplinary partnerships to ensure that AI technologies are developed, evaluated, and implemented in ways that are safe, equitable, clinically meaningful, and beneficial for children, adolescents, and young adults living with diabetes. Through education, knowledge exchange, research collaboration, and guidance development, the group seeks to help shape the future role of AI within pediatric diabetes care and within ISPAD.

VISION

A future in which artificial intelligence is used responsibly, safely, and equitably to improve diabetes outcomes, healthcare delivery, education, and quality of life for children, adolescents, and young adults living with diabetes worldwide.

MISSION

To lead international collaboration, education, guidance development, and knowledge exchange that support the responsible integration of artificial intelligence into pediatric diabetes care while promoting equity, safety, transparency, and improved health outcomes.

POTENTIAL OBJECTIVES
  1. Establish a global network of clinicians, researchers, educators, and other stakeholders interested in AI and pediatric diabetes.
  2. Promote a shared understanding of AI concepts, terminology, opportunities, and limitations in diabetes care.
  3. Support the development of educational resources, webinars, courses, and conference activities related to AI.
  4. Facilitate collaboration and research in areas such as clinical decision support, diabetes technology enhancement, and prediction of type 1 diabetes.
  5. Contribute to the development of practical guidance and consensus recommendations for healthcare professionals.
  6. Promote ethical, transparent, and equitable implementation of AI technologies across diverse healthcare settings.
  7. Encourage identification and mitigation of bias, inequities, and unintended consequences associated with AI systems.
  8. Foster collaboration with other ISPAD groups and committees to ensure coordinated and complementary activities in digital health and diabetes technology.
  9. Advocate for the responsible use of AI to improve the accessibility, affordability, and quality of diabetes care globally.